1. Home
  2. |Insights
  3. |CITIZEN SUIT WATCH: U.S. Supreme Court Agrees to Review Ninth Circuit Decision Requiring Clean Water Act Permits for Forest Roads

CITIZEN SUIT WATCH: U.S. Supreme Court Agrees to Review Ninth Circuit Decision Requiring Clean Water Act Permits for Forest Roads

Client Alert | 1 min read | 06.25.12

On June 25, 2012, the U.S. Supreme Court granted two petitions for writs of certiorari to review the decision of the U.S. Court of Appeals for the Ninth Circuit in Northwest Environmental Defense Center v. Brown, 640 F.3d 1063 (2011). The Ninth Circuit had ruled that storm water runoff from forest roads is subject to permitting under Clean Water Act section 402, 33 U.S.C. § 1342. The Ninth Circuit rejected the longstanding position of the U.S. Environmental Protection Agency ("EPA") that section 402 permits were not required for such runoff under the Agency's 1976 Silvicultural Rule – a position that EPA reaffirmed in its 1990 stormwater regulations implementing the 1987 amendments to the statute. (For a more detailed discussion of the Ninth Circuit's decision, click here)

Crowell & Moring filed an amicus brief on behalf of the National Alliance of Forest Owners, the American Farm Bureau Federation, and eleven other state and national trade associations all representing forest landowners (together, "Amici";) in support of the two petitions, focusing on the Ninth Circuit’s jurisdictional analysis, in addition to the court’s analysis of the merits under the Clean Water Act. (For a more detailed discussion of the Amici brief, click here.)

Insights

Client Alert | 4 min read | 04.29.24

Red Alert on the Orange Book: The FTC Continues to Crack Down on Improperly Listed Drug Patents

As reported in an earlier Client Alert, on November 7, 2023, the Federal Trade Commission challenged 100 patents as improperly listed in the Food and Drug Administration’s “Approved Drug Products with Therapeutic Equivalence Evaluations” publication, commonly known as the Orange Book. The FTC sent warning letters to ten drug and medical device manufacturers identifying patents for inhalers, autoinjectors and anti-inflammatory multi-dose bottles that the FTC believes are improperly listed. In the letters, the FTC indicated it is using the FDA’s regulatory dispute process to challenge the listing of these patents in the Orange Book because improperly listed patents may violate antitrust laws and impede competition.    ...